Enzymotec price target lowered to $26-$28 from $32-$34 at Wells Fargo Wells Fargo cut its price target range on Enzymotec after the company lowered its 2014 guidance. The firm is concerned by the company's growth deceleration but remains upbeat on its long-term growth outlook. It keeps an Outperform rating on the shares.
News For ENZY From The Last 14 Days
Check below for free stories on ENZY the last two weeks.